• 1.

    Word Health Organization (WHO), 2010. Control of the Leishmaniases: Report of a Meeting of the WHO Expert Committee on the Control of Leishmaniases. WHO technical report series no. 949. Geneva, Switzerland: Word Health Organization. Available at: http://www.who.int/neglected_diseases/integrated_media/integrated_media_2010_leishmaniasis_2/en/. Accessed March 21, 2017.

  • 2.

    Olliaro P, Vaillant M, Arana B, Grogl M, Modabber F, Magill A, Lapujade O, Buffet P, Alvar J, 2013. Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis. PLoS Negl Trop Dis 7: e2130.

    • Search Google Scholar
    • Export Citation
  • 3.

    Armijos RX, Weigel MM, Calvopina M, Mancheno M, Rodriguez R, 2004. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for new world cutaneous leishmaniasis. Acta Trop 91: 153160.

    • Search Google Scholar
    • Export Citation
  • 4.

    Organización Panamericana de la Salud (OPS), 2013. Leishmaniasis en las Américas: Recomendaciones para el Tratamiento. Washington, DC: Organización Panamericana de la Salud, 143. Available at: http://iris.paho.org/xmlui/handle/123456789/7704. Accessed March 21, 2017.

  • 5.

    Calvopina M, Armijos RX, Hashiguchi Y, 2004. Epidemiology of leishmaniasis in Ecuador: current status of knowledge—a review. Mem Inst Oswaldo Cruz 99: 663672.

    • Search Google Scholar
    • Export Citation
  • 6.

    Calvopina M, Loor R, Lara F, Zambrano P, Hashiguchi Y, 2012. Prevalencia y formas clínicas de las leishmaniasis en el noroccidente de la provincia de Pichincha – Ecuador. Rev Fac Cien Med (Quito) 37: 3138.

    • Search Google Scholar
    • Export Citation
  • 7.

    Calvopina M, Gomez EA, Uezato H, Kato H, Nonaka S, Hashiguchi Y, 2005. Atypical clinical variants in new world cutaneous leishmaniasis: disseminated, erysipeloid, and recidiva cutis due to Leishmania (V.) panamensis. Am J Trop Med Hyg 73: 281284.

    • Search Google Scholar
    • Export Citation
  • 8.

    Calvopina M, Kato H, Hashiguchi Y, 2013. Leishmaniasis recidiva cutis and its topical treatment in Ecuador. Trop Med Health 41: 9394.

  • 9.

    Calvopina M, Uezato H, Gomez EA, Korenaga M, Nonaka S, Hashiguchi Y, 2006. Leishmaniasis recidiva cutis due to Leishmania (Viannia) panamensis in subtropical Ecuador: isoenzymatic characterization. Int J Dermatol 45: 116120.

    • Search Google Scholar
    • Export Citation
  • 10.

    Calvopina M 2006. Leishmania isoenzyme polymorphisms in Ecuador: relationships with geographic distribution and clinical presentation. BMC Infect Dis 6: e139.

    • Search Google Scholar
    • Export Citation
  • 11.

    Kato H, Gomez EA, Martini-Robles L, Muzzio J, Velez L, Calvopina M, Romero-Alvarez D, Mimori T, Uezato H, Hashiguchi Y, 2016. Geographic distribution of Leishmania species in Ecuador based on the Cytochrome B gene sequence analysis. PLoS Negl Trop Dis 10: e0004844.

    • Search Google Scholar
    • Export Citation
  • 12.

    Guderian RH, Chico ME, Rogers MD, Pattishall KM, Grogl M, Berman JD, 1991. Placebo controlled treatment of Ecuadorian cutaneous leishmaniasis. Am J Trop Med Hyg 45: 9297.

    • Search Google Scholar
    • Export Citation
  • 13.

    Calvopina M, Martinez L, Hashiguchi Y, 2013. Cutaneous leishmaniasis “Chiclero’s Ulcer” in subtropical Ecuador. Am J Trop Med Hyg 89: 195196.

    • Search Google Scholar
    • Export Citation
  • 14.

    Armijos RX, Weigel MM, Izurieta R, Racines J, Zurita C, Herrera W, Vega M, 1997. The epidemiology of cutaneous leishmaniasis in subtropical Ecuador. Trop Med Int Health 2: 140152.

    • Search Google Scholar
    • Export Citation
  • 15.

    Soto J 2013. Intralesional antimony for single lesions of Bolivian cutaneous leishmaniasis. Clin Infect Dis 56: 12551260.

  • 16.

    Soto J, Paz D, Rivero D, Soto P, Quispe J, Toledo J, Berman J, 2016. Intralesional pentamidine: a novel therapy for single lesions of Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg 94: 852856.

    • Search Google Scholar
    • Export Citation
  • 17.

    Oliveira-Neto MP, Schubach A, Mattos M, da Costa SC, Pirmez C, 1997. Intralesional therapy of American cutaneous leishmaniasis with pentavalent antimony in Rio de Janeiro, Brazilian area of Leishmania (V.) braziliensis transmission. Int J Dermatol 36: 463468.

    • Search Google Scholar
    • Export Citation
  • 18.

    Vasconcellos EC 2012. Intralesional meglumine antimoniate for treatment of cutaneous leishmaniasis patients with contraindication to systemic therapy from Rio de Janeiro (2000 to 2006). Am J Trop Med Hyg 87: 257260.

    • Search Google Scholar
    • Export Citation
  • 19.

    Silva RE, Toledo A, Senna MC, Rabello A, Cota G, 2016. Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis: a retrospective review of a Brazilian referral centre. Mem Inst Oswaldo Cruz 111: 512516.

    • Search Google Scholar
    • Export Citation
  • 20.

    The Medical Letter, Inc., 2007. On Drugs and Therapeutics. Drugs for Parasitic Infections, 1st edition. New Rochelle, NY: The Medical Letter, Inc.

  • 21.

    Ferreira-Vasconcellos EC, Pimentel MI, Valete-Rosalino CM, Madeira MF, Schubach AO, 2014. Resolution of cutaneous leishmaniasis after acute eczema due to intralesional meglumine antimoniate. Rev Inst Med Trop Sao Paulo 56: 361362.

    • Search Google Scholar
    • Export Citation

 

 

 

 

Intralesional Infiltration with Meglumine Antimoniate for the Treatment of Leishmaniasis Recidiva Cutis in Ecuador

View More View Less
  • 1 Escuela de Medicina, Facultad de Ciencias de la Salud, Universidad De Las Américas (UDLA), Quito, Ecuador;
  • 2 Carrera de Medicina, Facultad de Ciencias Médicas, Universidad Central del Ecuador, Quito, Ecuador;
  • 3 Laboratorio de Patología Clínica, Carrera de Laboratorio Clínico, Universidad Central del Ecuador, Quito, Ecuador;
  • 4 Epidemiología, Distrito de Salud 17 D-12, Ministerio de Salud Pública del Ecuador, Quito, Ecuador

Meglumine Antimoniate (MA), administered intramuscularly for 21 continuous days is the recommended treatment of leishmaniases in Ecuador. However, because of its toxicity and requirement for intramuscular injections, treatment is frequently abandoned before completion. In addition, therapeutic failure and reactivation are not uncommon. Here we evaluate the efficacy and safety of MA administered intralesionally (IL) in leishmaniasis recidiva cutis (LRC). LRC is a special clinical variant of cutaneous leishmaniasis, characterized by reactivation at the edges of a primary cured lesion, presenting with active papules around the scar. Twenty-one patients were included in the study. All were diagnosed parasitologically by one of three diagnostic methods (smear, culture, and Leishmanin skin test). Each patient received MA intralesionally weekly for 4 weeks. Each papule was infiltrated until complete saturation. On average, patients received 1 mL of MA per administration. The criterion of cure was the complete resolution of the papules. Follow up was performed at 30, 90, and 180 days after treatment. At day 30 after treatment, 19 (90.5%) of 21 patients were clinically cured. The two patients, who did not heal by the fourth application, were cured on the seventh and eighth dose, achieving a clinical cure of 100% without subsequent reactivation. Mild to moderate local pain during infiltration was the only adverse reaction experienced by 81% of patients. In one case, subsequent infiltrations were discontinued because of a local allergic reaction. Complete compliance of patients to treatment and the small volume of drug administered make this method of administering MA an effective, safe, and inexpensive alternative. Consequently, IL could replace intramuscular administration in the treatment of LRC in Ecuador.

Author Notes

Address correspondence to Manuel Calvopiña, Universidad De Las Américas (UDLA), Av. Granados E11-41 y Colimíes, P.O. Box 17-17-9788, Quito 170137, Ecuador. E-mail: manuel.calvopina@udla.edu.ec

Financial support: Proyectos Semilla, Comisión de Investigación Formativa, Universidad Central del Ecuador (cif-cv-fcm-16). In part by the Fundação de Assistência Médica Internacional (AMI) by Fernando Nobre, President of AMI, Lisboa, Portugal under the Project “Integrated Control of Leishmaniasis in Ecuador” (ICLE).

Authors’ addresses: Manuel Calvopiña, Escuela de Medicina, Universidad De Las Américas (UDLA) Quito, Ecuador, E-mail: manuel.calvopina@udla.edu.ec. William Cevallos, Edison Puebla, Jessica Flores, and Richard Loor, Carrera de Medicina, Universidad Central del Ecuador, Quito, Ecuador, E-mails: wcevallos@uce.edu.ec, puebla.edison@gmail.com, jessicaflores.uce.felsocem@outlook.es, and rieduard-09@hotmail.com. Yolanda Paredes, Laboratorio de Patología Clínica, Carrera de Laboratorio Clínico, Universidad Central del Ecuador, Quito, Ecuador, E-mail: paredesyolanda@yahoo.com. José Padilla, Epidemiología, Distrito de Salud 17 D-12, Ministerio de Salud Pública del Ecuador, Quito, Ecuador, E-mail: jose.padilla@17d12.mspz2.gob.ec.

Save